Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by mjn797979on Oct 26, 2020 11:01pm
61 Views
Post# 31786430

RE:RE:RE:RE:RE:RE:RE:RE:Knight Signs New Exclusive AmBisome® Agreement with Gilead

RE:RE:RE:RE:RE:RE:RE:RE:Knight Signs New Exclusive AmBisome® Agreement with Gilead Definitely not market impacting news event.

Their news release are never met with any rally following them.
I mean you can blame the broader market being down considerably today but it's been ripping since the spring and GUD is still down big.

Clearly investor fatigue in this stock, their cash position is eroding sitting there not being used to make money and what is there to really get investors excited other than painfully slow growth.

Its almost like investors can come back in 3 years and nibble at this stock at the same price it is at today. 

Can they acquire something else? They have money sitting there doing nothing.

2020 has been a huge setback for Knight, I almost want to say can it get any worse but it always can.




Bullboard Posts